TY - JOUR T1 - Comparison of interim PET response to second-line vs. to first-line treatment in classical Hodgkin lymphoma – contribution to the development of response criteria for relapsed or progressive disease JF - Journal of Nuclear Medicine JO - J Nucl Med DO - 10.2967/jnumed.120.247924 SP - jnumed.120.247924 AU - Regine Kluge AU - Tim Wittig AU - Thomas Walter Georgi AU - Lars Kurch AU - Osama Sabri AU - W. Hamish Wallace AU - Tomasz Klekawka AU - Ana Fernández-Teijeiro AU - Francesco Ceppi AU - Jonas Karlén AU - Jane Pears AU - Michaela Cepelová AU - Alexander Fosså AU - Auke Beishuizen AU - Lisa Lyngsie Hjalgrim AU - Dieter Körholz AU - Christine Mauz-Körholz AU - Dirk Hasenclever Y1 - 2020/12/01 UR - http://jnm.snmjournals.org/content/early/2020/12/18/jnumed.120.247924.abstract N2 - Rationale: In first-line treatment of Hodgkin lymphoma (HL) Deauville scores 1-3 define complete metabolic remission. Interim FDG-PET is also used for relapse treatment adaptation, however PET-response criteria are not validated for relapse treatment. Methods: We performed a pairwise comparative analysis of early treatment response to first-line and to second-line treatment in 127 patients with classical Hodgkin lymphoma who experienced relapse. Patients participated in the prospective, multicenter EuroNet-PHL-C1 study. Residual uptake was measured retrospectively using the qPET method, a validated semiautomatic quantitative extension of the Deauville score. Empirical cumulative distribution functions (ECDF) of the qPET values were used to systematically analyze the response to first-line and second-line treatment. Results and Conclusion: Individual patients responded variably to first-line and second line treatment. However, the ECDF of the qPET values from all patients were nearly superimposable. This supports that first-line and second-line treatment in HL do not require different response criteria. ER -